In March 2023, Moderna CEO Stéphane Bancel gathered roughly 100 of the company’s senior executives at an off-site leadership meeting. Mid-stage results from their experimental cancer vaccine had just come in and looked promising.
Bancel asked a simple question: how many of you actually believed this was going to work? He invited anyone who did to stand up.
Moderna’s president, Stephen Hoge, was standing on stage. He sat down. Then Bancel sat down too. Nobody stood.
“None of us believed it,” Hoge later recalled. It took time before the feeling arrived — “Oh my gosh. This is real.”
The rest of the world took even longer to come around. That changed on August 19, 2026, when Moderna and Merck announced that their personalised mRNA cancer vaccine, intismeran autogene, had succeeded in a large Phase 3 clinical trial — the first time any mRNA-based cancer treatment had cleared that bar. It is a result a decade in the making, built on a foundation of doubt, logistical complexity, and a pandemic that threatened to derail the entire programme.
A Decade of Development Nobody Took Seriously
Moderna began developing the technology behind intismeran as far back as 2017, entering a 50/50 partnership with Merck the following year. The concept was audacious: rather than targeting a shared cancer antigen common to all tumours, they would build a different vaccine for every single patient, sequenced and manufactured from scratch based on the unique mutational signature of their individual tumour.
Each vaccine contains mRNA coding for up to 34 neoantigens — proteins specific to that patient’s cancer cells — selected by an AI algorithm that analyses the tumour’s DNA and identifies the mutations most likely to provoke a strong immune response. Administered alongside Merck’s immunotherapy drug Keytruda, the combination was designed to work after surgery: attacking any remaining cancer cells and training the immune system to recognise and destroy them if they returned.
The idea was scientifically compelling. It was also extraordinarily logistically complex, enormously expensive, and — for most of the period it was in development — widely regarded as unlikely to work.
What the Results Show
The Phase 3 trial, known as INTerpath-001, enrolled 1,137 patients with high-risk melanoma that had been surgically removed. Half received intismeran plus Keytruda; half received Keytruda alone. The combination produced statistically significant improvements in recurrence-free survival and in the rate of distant spread — meaning patients who received the vaccine were meaningfully less likely to see their cancer come back or travel to other organs.
Five-year follow-up data from an earlier Phase 2 trial, presented in June 2026, had already shown the combination cutting the risk of recurrence or death by 49% compared to Keytruda alone. No new safety signals emerged. The companies described the results as a landmark moment in adjuvant melanoma treatment — treating the period after surgery to prevent return — and they appear to be right.
If regulators approve the combination, intismeran autogene could be available to high-risk melanoma patients as early as 2027.
Bigger Than Melanoma
Melanoma is where the evidence is strongest, but it is far from the only target. The INTerpath programme is already testing intismeran in lung, bladder, kidney, and other cancers. Eight Phase 2 and Phase 3 studies are currently underway across different tumour types.
The implications extend beyond Moderna and Merck. BioNTech — whose mRNA platform underpinned the Pfizer COVID vaccine — is running similar trials of its own personalised cancer vaccine in colorectal and pancreatic cancer, with results expected from 2027 onwards. The success of intismeran has energised the entire field.
“We should be hearing results from multiple studies over the next few years,” said one leading oncologist, “and there’s every reason to hope, with this news, that many of them will be positive.”
The Sceptics Are Still There
Despite the result, some observers are urging caution. The companies have so far released top-line data only — full results are expected to be presented at a medical conference before any regulatory submission. And investors, who had been betting against Moderna’s stock right up until the announcement, have not universally converted. The mRNA cancer vaccine field has seen promising early signals before that did not survive the rigour of larger trials.
The political environment adds another layer of uncertainty. Federal support for mRNA research in the US has become contested, with significant government funding for mRNA vaccine programmes cut in 2025. Whether that political climate will complicate the regulatory path or affect public uptake of any approved treatment remains an open question.
The Breakthrough Nobody Stood Up For
There is something almost poignant about the image of an entire room of executives sitting down, including the CEO who built the company, because none of them truly believed their own drug would work.
Science often moves like this — not through confident strides toward a known destination, but through years of uncertain, expensive, disbelieved effort that suddenly and without ceremony produces something real. The cancer vaccine nobody believed in has, against the collective expectations of almost everyone involved in building it, apparently worked.
What comes next — regulatory approval, expanded trials, adoption across cancer types — will take years to fully unfold. But August 19, 2026 is likely to be remembered as the day the mRNA cancer vaccine stopped being a bet and became a result.